The administration of antigens in soluble form can induce antigen-specific immune tolerance and suppress experimental autoimmune diseases. In a marmoset model of multiple sclerosis induced by myelin oligodendrocyte glycoprotein (MOG), marmosets tolerized to MOG were protected against acute disease, but after tolerization treatment a lethal demyelinating disorder emerged. In these animals, MOG-specific T cell proliferative responses were transiently suppressed, cytokine production was shifted from a T helper type 1 ( T H 1) to a T H 2 pattern, and titers of autoantibodies to MOG were enhanced. Thus, immune deviation can increase concentrations of pathogenic autoantibodies and in some circumstances exacerbate autoimmune disease.
Experimental allergic encephalomyelitis
(EAE) is an autoimmune disease of the central nervous system (CNS) that serves as a laboratory model for the human demyelinating disease multiple sclerosis (MS) (1, 2) . In rodents, EAE is mediated by effector T cells that respond to myelin antigens and secrete proinflammatory (T H 1) cytokines, primarily interleukin-2 (IL-2), tumor necrosis factor-␣ (TNF-␣), and interferon-␥ (IFN-␥) (3) . The therapeutic administration of myelin antigens in nonimmunogenic form can suppress disease-inducing T cells and protect against EAE (4) . This protection may result from enhanced production of anti-inflammatory (T H 2) cytokines, notably , an effect known as immune deviation (6). Protection can be conferred by adoptive transfer of antigen-specific T H 2 cells or administration of T H 2 cytokines, and is abrogated by antibodies to IL-4 (7).
We have developed a primary demyelinating form of EAE in the common marmoset Callithrix jacchus that has a clinical and pathological similarities to human MS (8, 9) . In this species, synergistic T cell and B cell responses result in the MS-like lesion. Diverse populations of T H 1-cells recognizing myelin basic protein (MBP) or myelin oligodendrocyte glycoprotein (MOG) mediate the inflammatory component of the lesion, whereas antibodies to MOG mediate demyelination (9). Thus, MOG, a minor constituent of myelin comprising less than 0.05% of myelin proteins by weight, is a major encephalitogenic antigen capable of inducing pathogenic T cell and B cell responses in C. jacchus. Here, we characterize the effects of immune deviation in this model. Seven C. jacchus marmosets were immunized with a recombinant protein corresponding to the extracellular domain of rat MOG (rMOG) in adjuvant (10). From day 7 to day 18 after immunization, animals received either soluble rMOG (rMOGtolerized) or placebo (control-tolerized). Consistent with previous observations in rMOG-immunized marmosets (9), clinical signs of EAE developed in four controltolerized animals between 9 and 16 days after immunization. In contrast, in the three animals treated with soluble rMOG, signs of EAE were suppressed, indicating that tolerization was successful. However, after cessation of treatment a rapidly progressive, lethal form of hyperacute EAE developed that was clinically more severe than in controls (Fig. 1) or than in any of more than 40 previously studied marmosets with acute EAE.
Neuropathologic findings confirmed the presence of widespread and histologically severe lesions. Lesions in the cerebral hemispheres and spinal cord of rMOG-tolerized animals were visible to the naked eye and were microscopically centered on blood vessels around which there was residual inflammation rich in plasma cells, demyelination, and macrophage activity. In the spinal cord and optic nerve (Fig. 2) , lesions consisted of broad bands of subpial and perivascular white matter involvement. In contrast to control-tolerized animals in which lesion activity was limited to perivascular and subpial areas, in rMOG-tolerized animals there was a prominent zone of myelin pallor, sometimes up to 2 mm in width, surrounding a narrow band of demyelination and extending into the adjacent white matter. Within this zone of myelin pathology, cellular infiltration was absent and affected nerve fibers displayed dilated myelin sheaths with the axon either lying to one side of a large myelin vacuole or within a web of Fig. 1 . Clinical course of EAE in placebo-treated and rMOG-treated C. jacchus marmosets. Animals were treated from day 7 until day 18 (shaded area) after immunization and received either 300 g of rMOG dissolved in 0.025M Naacetate buffer, pH 3.0 (left panel) or placebo [right panel: buffer alone, recombinant glutathione-Stransferase (rGST), or cytochrome c] by intraperitoneal injection every other day for a total of six injections. Clinical signs were graded by blinded observers according to a scale of 1 to 5 as described (19) . dissociated membranes. These changes, confirmed at the ultrastructural level, suggested that the CNS demyelination was humorally mediated (11) . Within this zone of myelin vacuolation, except for a small number of oligodendrocytes that displayed evidence of cytolysis but not apoptosis, oligodendrocyte degeneration was not seen. The histopathologic and ultrastructural characteristics of these lesions were similar to those of typical acute MS (12) .
Consistent with previous experience (9), control-tolerized marmosets developed T cell proliferative responses to rMOG in circulating peripheral blood mononuclear cells (PBMCs) and in lymph node cells (LNCs). In contrast, no response could be detected in any rMOG-tolerized marmoset during the period of antigen administration (Fig.  3 ), but after treatment proliferative responses appeared concurrent with the development of lethal EAE. Circulating antibodies to rMOG were present in all animals in both groups; however, by day 21 after immunization, titers were higher in rMOGtolerized animals despite the fact that they remained asymptomatic (Fig. 4, A and B) . Epitope mapping studies indicated that rMOG-tolerized and control marmosets developed antibodies to rMOG with similar fine specificities (Fig. 4C) . At the time of lethal EAE, rMOG-tolerized marmosets had identical proliferative responses to rMOG as did controls, but autoantibodies were detected in serum at dilutions that were four-to eightfold higher (Figs. 3 and 4) . Prior studies indicated that polyclonal marmoset antibodies to MOG can transfer severe demyelination in marmosets, but only in the presence of disease-inducing T cells capable of disrupting the blood brain barrier (9). In hyperacute EAE, it is likely that antibody-mediated demyelination was similarly facilitated by disease-inducing T cells that were activated after cessation of tolerance treatment.
Cytokine gene expression was measured in LNC and PBMC by reverse transcriptase-polymerase chain reaction (RT-PCR) after stimulation in vitro with either rMOG or MBP. Compared to control-tolerized animals, rMOG-tolerized marmosets had increased synthesis of IL-10 and IL-6 mRNA, and decreased IFN-␥ and TNF-␣ mRNA, in response to stimulation with rMOG (Fig. 5) . No significant stimulation of any cytokine mRNA was observed after stimulation with MBP. The shift from a T H 1-like to a T H 2-like pattern of cytokine production in response to rMOG was present by day 14 after immunization, and persisted until the end of the study. The inability to detect a proliferative response to rMOG in tolerized animals may have resulted from antiproliferative effects of T H 2 cytokines (13), from reversible T cell anergy or apoptotic T cell death (14) . The appearance of proliferative responses after cessation of treatment suggested that the state of unresponsiveness was reversible.
Our data show that induction of a T H 2 response may exacerbate autoimmunity by enhancing production of pathogenic autoantibodies. This effect is likely mediated by the known functions of T H 2 cytokines on induction of B cell differentiation, switch of immunoglobulin production from low-affinity immunoglobulin M (IgM) to highaffinity IgG, and synthesis of IgG1 (6, 15) . In human MS, T cell mediation is one likely pathogenic mechanism (2, 16) , but myelinspecific autoantibodies are also present (17) and antibody-and complement-mediated tissue damage may occur (18) . This raises the possibility that in MS, as in C. jacchus EAE, induction of a T H 2 response to myelin antigens might promote humoral autoimmunity. Strategies that induce long-term tolerance both for T cells and B cells may be required for successful immunotherapy of complex autoimmune disorders. . 3 . T cell responses in PBMC of control-tolerized and rMOG-tolerized marmosets. T cell proliferative responses were measured by a standard proliferation assay (9). Briefly, 10 5 cells were plated in triplicate in 96 well plates at a cell density of 10 6 cells/ml in AIM-V medium (Gibco-BRL). The following antigens were added to the wells: none (control), rMOG (10 g/ml), or phytohemagglutinin (2.5 g/ml). After 48 hours, 0.5 Ci per well of [ Today 17, 225 (1996) . 7. V. K. Kuchroo et al., Cell 80, 707 (1995) ; M. K. Racke et al., J. Exp. Med. 180, 1961 Ann. Neurol. 37, 519 (1995) . 9. C. P. Genain et al., J. Clin. Invest. 96, 2966 . 10. C. jacchus marmosets used for these studies were from the New England Primate Research Center (Southborough, MA). Animals were cared for in accordance with the guidelines of the Institutional Committee on Care and Use of Laboratory Animals. A maximum of 2.5 ml of blood every other week was taken from each animal. All procedures were done under brief anesthesia administered intramuscularly [ketamine (10 to 20 mg/kg) and midazolam (0.1 mg/kg)]. Fifty micrograms of rMOG were dissolved in 100 l of phosphate-buffered saline and emulsified with an equal volume of complete Freund's adjuvant (Gibco-BRL) containing killed Mycobacterium tuberculosis (3 mg/ml, H37Ra, Difco), and administered intradermally in four injection sites on the scapular and hip regions. On the day of immunization, and again 2 days later, 10 10 inactivated Bordetella pertussis organisms diluted in 5 ml of isotonic saline were administered intravenously. At the termination of the experiments animals were euthanized under pentobarbital anesthesia by intracardiac perfusion with 2.5% buffered glutaraldehyde solution. rMOG is a nonglycosylated recombinant fusion protein containing the extracellular domain (residues 1 to 124) of rat MOG (20) . Although the sequence of marmoset MOG is not known, this domain of the protein is highly conserved between species (21), and rMOG is encephalitogenic in C. jacchus marmosets (9). 6 LNC were cultured in 1 ml AIM-V in the presence of: no antigen (control); rMOG (10 g/ml) or MBP (50 g/ml). After 4 hours, cells were harvested and total RNA extracted using TriZol (Gibco-BRL). A first strand cDNA was synthesized using 2.5 g of total RNA in a 100 l reaction containing PCR buffer (Promega), 1.5 mM MgCl 2 , 1 unit of Moloney murine leukemia virus reverse transcriptase (Gibco-BRL), 1 mM dNTP, 25 nM random hexamers and ribonuclease inhibitor (Pharmacia). Ten microliters of cDNA was used for PCR amplification in a 25-l reaction in the presence of PCR buffer, 0.5 mM MgCl 2 , 1 unit of Taq polymerase (Gibco), and 0.5 M of each of G3PDH upstream and downstream primers (as internal control for the RT-PCR reaction) and primers specific for TNF-␣, IFN-␥, IL-10, and IL-6 (22).
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Society (C.P.G.). rGST was supplied by R. H. Edwards and D. Krantz, and Bordetella pertussis from Wyeth Lederle Vaccine and Pediatrics, Pearl River, NY. We thank J. R. Oksenberg for helpful discussions and K. Lovett and L. Brovarney for their dedicated work with the animals. The mature breast contains lobules, clusters of closed glandular spaces that produce milk during lactation. These lobules are connected to the nipple-areolar complex by a system of branching ducts that are surrounded by varying amounts of fat and connective tissue. Breast cancer is thought to develop within a terminal ductal-lobular unit (TDLU), which includes the lobule and its most proximal ducts (1) . Breast cancer evolves by clonal selection of cells that acquire multiple molecular changes. One model suggests that breast cancer, like colon cancer (2), develops through a defined progression of morphologically distinguishable stages beginning with benign hyperplasia, which progresses to atypical hyperplasia, then to in situ carcinoma, and finally to invasive cancer (1) . This sequential progression may not be the only way that breast cancers develop, however. Many small invasive cancers do not have atypical components, which suggests that they may have developed directly from morphologically normal epithelium. If this were true, one might expect to find evidence of a "field effect" in which at least some of the genetic aberrations found in invasive cancers are also present in the morphologically normal epithelium.
To test this hypothesis, we carefully microdissected hematoxylin-eosin-stained sections of breast cancers so as to isolate morphologically discrete regions (Fig.  1A) . DNA was prepared from malignant areas of the section and from adjacent normal TDLUs. As a control for each case, DNA was also prepared from normal breast skin (usually from a separate section) that had been similarly microdissected. We studied LOH at chromosome 3p24, 11p15.5, 13q13, and 17p13.1 because these loci show LOH in a high percentage (ϳ30 to 60%) of invasive ductal breast cancers (3, 4) . For the carcinomatous regions, the frequency of LOH at 3p24 (48%) and 11p15.5 (29%) was similar to that previously reported (4) . The frequency of LOH in the invasive components was higher than the literature values for 13q13 (64% here versus ϳ40%) and for 17p13.1 (80% here versus ϳ60%). These discrepancies may be due to random variation because our sample size was small.
In 8 of 30 cases we detected LOH in the adjacent morphologically normal TDLUs (Table 1) . In all eight cases, the same allele was missing in the adjacent carcinoma (Fig.  2, A and B) . LOH in normal TDLUs was seen in 6 of the 10 cases where LOH at 3p24 was found in the carcinoma. LOH at 11p15.5 in the normal TDLUs was seen in one of five cases with this LOH in the carcinoma; LOH at 17p13.1 in the normal TDLUs was seen in 1 of 16 cases with this LOH in the carcinoma. None of 10 cases with LOH at 13q13 in the carcinoma had this lesion in the normal TDLUs. Among tumors with and without LOH in adjacent normal tissues, there was no significant difference in grade, hormone receptor status, (A) One of the TDLUs (solid arrow) subsequently used for microdissection. The surrounding stroma was scraped away with a scalpel, and a clean blade used to remove the TDLU to a test tube for DNA extraction (11, 14) . Note that the carcinoma areas (open arrow) are clearly separated from the morphologically normal TDLUs (hematoxylin-eosin stain). (B) The same TDLU as in (A) before removal of the surrounding stroma. The higher magnification illustrates that it is histologically normal (hematoxylin-eosin stain). (C) Overexpression of HER-2/neu in the malignant epithelial cells, detected by immunostaining of the surface membranes (large arrow); cells in the adjacent TDLU (small arrow) show no immunostaining. Scale bars indicate 150 m in (A) and 30 m in (B) and (C).
